Stem Cell Therapy for Knees in Mexico: Evidence, Candidacy, Cost and What to Expect
Stem cell therapy for knees uses adult mesenchymal stem cells injected directly into the knee joint, with the aim of calming inflammation and easing pain. Randomised trials of the cell types used at GIOSTAR Mexico, donor-derived (allogeneic) mesenchymal stem cells from adipose tissue or umbilical cord tissue, report improvement in pain and function at 6 and 12 months, alongside a consistent safety record. This is an emerging therapy rather than a settled one: research is still establishing how much benefit, for how long, and for whom, and structural cartilage repair has not yet been shown. Whether it suits your knee is something a physician determines from your imaging.
If you are reading this, you have probably already tried the usual things. Anti-inflammatories. A cortisone shot that worked for a while. Physical therapy that helped, then plateaued. Somewhere in that process a surgeon mentioned knee replacement, and you started looking for something in between.
This page is written for that moment. It covers what stem cell therapy for knees actually is, what the published research supports and where it falls short, why the cell source and the laboratory that prepares it matter, who tends to be a candidate and who does not, what treatment at GIOSTAR Mexico involves step by step, and what it costs. It also gives you ten questions to ask any clinic (including this one) before you pay anything.
GIOSTAR Mexico operates COFEPRIS-certified clinics in Playa del Carmen, Cancun and Los Algodones, and prepares its cells under Good Manufacturing Practice conditions with per-batch testing before release. Its clinical and research protocols were established by Dr. Anand Srivastava, Chairman and Co-Founder of GIOSTAR.
🔍 Table of Contents
• What stem cell therapy for knees involves
• What the research shows for knee stem cell treatment
• Why the laboratory behind your cells matters
• Who may be a candidate, and when stem cell therapy for knees may not be appropriate
• How knee stem cell treatment is delivered at GIOSTAR Mexico
• Why patients evaluate Mexico for knee stem cell therapy
• Knee stem cell treatment compared with PRP, cortisone, physical therapy and knee replacement
• Knee stem cell therapy cost at GIOSTAR Mexico
• What is arranged for you once you are accepted
• How to evaluate any knee stem cell clinic before you pay
What stem cell therapy for knees involves
Mesenchymal stem cells (MSCs) are adult cells that can develop into several tissue types, including cartilage and bone. In a knee protocol they are delivered by intra-articular injection, an injection placed directly into the joint space itself, rather than into the muscle or the bloodstream. You may also see this described as stem cell injections for the knee; our evidence guide to knee injections covers that research in detail.
Here is where precision matters, and where this page goes into more detail than most.
Where the cells come from is not a detail. There are two broad sourcing models, and they are not interchangeable:
- Autologous. Your own cells, harvested from your fat by liposuction or from your bone marrow by aspiration, then either minimally processed or expanded in a laboratory. You undergo a second procedure to obtain them, and the quality of what is harvested varies with your age and your health.
- Allogeneic. Cells from a screened healthy donor, expanded and characterised in a laboratory in advance, then released in defined doses. No harvest procedure is required from you, and every patient in a batch receives a product made to the same specification.
GIOSTAR Mexico protocols use allogeneic adult mesenchymal stem cells, derived from adipose tissue or umbilical cord tissue depending on the protocol. Adipose-derived cells come from healthy donors between 18 and 22 years of age, screened through cytotoxicity and oncogenicity testing before use. Umbilical cord-derived cells are collected from donated cord tissue following healthy births; they are adult mesenchymal stem cells, not embryonic cells, and no embryo is involved at any point.
What is mechanism: Laboratory and animal research indicates that MSCs release signalling molecules that dampen inflammation and influence the local joint environment, and that they have the capacity to differentiate into cartilage-producing cells. This is the biological rationale for using them in a degenerating knee.
What is demonstrated outcome: A growing body of trial evidence, set out in full in the next section. Mechanism explains why researchers pursue this treatment; trial results tell you how it has actually performed. Both belong in your decision, and you deserve to see them presented separately rather than blended together.
You can read more about how stem cells are administered across different protocols.
What the research shows for knee stem cell treatment
This is the section most clinic pages skip. It is here because a confident decision is built on it.
Most pages on this subject quote findings about “stem cell injections” as a single category. That category pools dozens of different products (different tissue of origin, different donors, different preparation methods, different doses) under one label, which tells you about the field in general and very little about any particular treatment.
The more useful question is narrower, and the answer to it is more encouraging: what have randomised trials shown for the specific type of cells you would receive?
Allogeneic adipose-derived MSCs
- MAG200 phase I/IIa randomised controlled trial (2024) [2]. Forty participants with moderate knee osteoarthritis received a single intra-articular injection of an allogeneic adipose-derived MSC preparation across four ascending dose cohorts (10, 20, 50 and 100 million cells) or placebo, followed for 12 months. Treatment was well tolerated with no treatment-related serious adverse events. The MAG200 cohorts reported a greater proportion of responders than placebo, with statistically significant improvement in pain and clinically relevant improvement across all KOOS subscales. The authors present it as supportive early-phase evidence, strong enough to justify advancing the preparation to later-stage trials.
- Network meta-analysis of autologous versus allogeneic adipose-derived MSCs (Kasagga A et al., Cureus, 21 April 2025) [3]. Eight randomised trials in Kellgren-Lawrence grade II–IV knee osteoarthritis. High-dose allogeneic adipose-derived MSCs ranked highest of all compared options for functional improvement at 6 and 12 months (WOMAC SUCRA 74.6% and 71.71%). Serious adverse events were rare across the included trials and were judged unrelated to treatment.
- Meta-analysis of MSC injection in unoperated knee osteoarthritis (Cao M et al., Stem Cell Research & Therapy, 7 March 2025;16:122) [4]. Eight randomised trials, 502 patients. Compared with controls, MSCs significantly improved WOMAC scores at 6 months (mean difference 7.44, 95% CI 1.45–13.42, P = 0.01) and at 12 months (mean difference 10.31, 95% CI 0.96–19.67, P = 0.03), with improvement in VAS pain and KOOS at both time points. Subgroup analysis found the effect more pronounced with adipose-source cells and higher doses.
Allogeneic umbilical cord MSCs
- Matas J et al., Stem Cells Translational Medicine, 2019;8(3):215–224 [5]. A controlled randomised phase I/II trial in 26 patients with symptomatic knee osteoarthritis, comparing hyaluronic acid (n = 8), a single 20-million-cell dose of umbilical cord-derived MSCs (n = 9), and repeated dosing at baseline and six months (n = 9). Repeated UC-MSC dosing outperformed both the single dose and hyaluronic acid on pain and function outcomes. Worth noting for this page: the cells were cultured in an ISO 9001:2015-certified, GMP-type laboratory. The trials that produce the cleaner results are the ones using a defined, quality-controlled product.
- Matas J et al., Stem Cells Translational Medicine, 2024;13(3):193–203 [6]. A phase I dose-escalation trial assessing safety and efficacy of umbilical cord-derived MSCs in knee osteoarthritis, run alongside a preclinical dose-response evaluation.
- Pico OA et al., Cytotherapy, 2025;27(2):188–200 [7]. A randomised, double-blind, controlled pilot study in 30 patients with Kellgren-Lawrence grade II–III knee osteoarthritis, comparing a single injection of a standardised UC-MSC product against triamcinolone, a corticosteroid, over 12 months. The cell-treated group showed significantly greater improvement in WOMAC (including all three subscales), pain rating and SF-36 quality of life than the corticosteroid group, sustained across the full 12 months, with no severe adverse events reported.
How it compares with a corticosteroid injection
The largest randomised comparison to date is Mautner K et al., Nature Medicine, 2023;29(12):3120–3126 [8], which randomised 480 patients with knee osteoarthritis across four arms, including allogeneic umbilical cord tissue-derived MSCs, with corticosteroid injection as the comparator. All groups improved on pain scores over 12 months, and the cell-treated patients performed on a par with corticosteroid injection, the established standard of care for symptomatic relief. No procedure-related serious adverse events were reported.
Read alongside the Pico trial, where a standardised umbilical cord product outperformed a corticosteroid over the same 12 months, the picture is of a therapy performing at least as well as the conventional injection option, and in some trials better, while avoiding the cartilage concerns associated with repeated steroid use.
The wider picture
Together these trials describe a therapy with a consistent safety record and measured improvement in pain and function over 6 to 12 months. The broadest synthesis available, a 2025 Cochrane systematic review of 25 randomised trials in 1,341 participants [1], likewise found improvement in pain and function up to six months, and rated its confidence low largely because the cell source, preparation and dose varied so widely across the studies it pooled.
That last observation is the most useful sentence in the review for anyone choosing a clinic, and the next section explains why. Research continues on how long benefit lasts beyond a year and on structural change within the joint; GIOSTAR Mexico presents this as an emerging therapy that works alongside conventional orthopedic care, with candidacy assessed case by case.
For a deeper look at the trial literature, see what the research says about knee osteoarthritis.
Why the laboratory behind your cells matters
Here is why that observation about varying cell source, preparation and dose matters so much. Cell products are biological, not chemical. Two vials described with the same words can differ in viability, potency, purity and dose. That variability is the single biggest reason the field’s evidence is still rated low certainty. It is also the one variable a clinic can actually control.
This is why GIOSTAR Mexico’s answer to “what are you injecting?” is a manufacturing answer, not a marketing one.
Good Manufacturing Practice conditions. Cells are prepared under GMP conditions, the same class of controlled-environment, documented-process standard applied to pharmaceutical production, covering facility, personnel, materials and record-keeping.
Per-batch testing before release. A cell product cannot be quality-tested the way a mass-produced tablet can. Batch release testing is what stands in for that: each batch is tested and must meet release criteria before any of it is administered.
Donor screening. Adipose-derived cells come from healthy donors between 18 and 22 years of age, screened through cytotoxicity and oncogenicity testing before use. Umbilical cord tissue is donated following healthy births.
COFEPRIS certification. The clinics in Playa del Carmen, Cancun and Los Algodones are certified by COFEPRIS, Mexico’s federal health regulator.
Defined dosing. Protocols for joint conditions, including the knee, administer between 105 and 140 million stem cells. Your exact cell count is set by your protocol and stated to you in advance, rather than injecting an unquantified preparation.
Two points of context, so you can weigh this properly:
- Certification governs the product, not the outcome. Manufacturing quality controls one important source of variability. It is a sound reason for confidence in what you receive, and it works alongside the efficacy evidence rather than standing in for it.
- The published trials above used their own products, not ours. MAG200, Cellistem and the preparations in the Matas trials are specific investigational products with their own manufacturing records. Their results are evidence for allogeneic MSC therapy as a modality, and that is precisely how this page presents them.
What quality control does buy you is a product that can be described to you precisely: known origin, known dose, tested before release. The International Society for Stem Cell Research encourages patients to ask exactly that, and a documented cell source is one of the clearest signals of a well-run program [10].
Who may be a candidate, and when stem cell therapy for knees may not be appropriate
Candidacy is not decided from a phone call or a form. It is decided after a physician has looked at your imaging.
You may be a reasonable candidate if:
- Your knee osteoarthritis is early to moderate, with cartilage still present on imaging. Most of the trials above enrolled patients at Kellgren-Lawrence grade II–III, which is the population the evidence actually speaks to.
- You have pain and stiffness that limit daily activity, and conservative treatment has stopped helping.
- You are not a candidate for knee replacement yet, or you want to postpone it.
- Your general health supports an outpatient procedure and travel.
- You understand this is an emerging therapy and are approaching it with realistic expectations.
Stem cell injections may not be the right fit if:
- Your imaging shows advanced, bone-on-bone degeneration with little remaining cartilage. There is limited tissue for the cells to work with, and other approaches are likely to serve you better.
- The knee is structurally unstable, or there is significant ligament or meniscal damage that would need surgical repair.
- Your knee pain is mechanical (locking, giving way, a torn meniscus) rather than inflammatory and degenerative.
- You are pregnant, or you have an active infection, active cancer or an uncontrolled systemic condition.
- You are looking for a guaranteed alternative to surgery. We would rather set expectations you can rely on than promise an outcome nobody can guarantee.
Because GIOSTAR Mexico’s protocols use donor-derived cells, candidacy does not depend on your own tissue. There is no liposuction and no bone marrow aspiration to obtain the cells, and no second recovery to manage. That is a practical consideration for older patients and for anyone travelling.
GIOSTAR Mexico does not offer stem cell therapy for eye conditions, including macular degeneration, and does not offer it to patients who are pregnant, have an active infection or have active cancer. These exclusions apply to stem cell therapy specifically. For cancer patients, GIOSTAR Mexico offers a separate cellular immunotherapy program, with its own evaluation and eligibility criteria. Every patient is evaluated individually, and where treatment could pose a health risk, we determine it is not an appropriate option. GIOSTAR Mexico’s screening is built to give you a straight answer either way. When the answer is no, you will be told why and pointed toward what may help instead. That candour is part of the care.
How knee stem cell treatment is delivered at GIOSTAR Mexico
Seven stages, in this order.
- Evaluation. A no-cost consultation with a patient coordinator, then a health-history review. You describe symptom history, prior treatments, previous surgery, current medications and general health.
- Imaging and laboratory review. You submit existing knee imaging (X-ray or MRI) for physician review, along with baseline bloodwork. This is the gate. No protocol is designed and no treatment date is offered before this review is complete.
- Protocol design. If you are accepted, a protocol is set for your specific knee, based on the degree of degeneration seen on imaging and your clinical picture. GIOSTAR Mexico’s protocols were established by Dr. Anand Srivastava.
- Laboratory processing. Cells are prepared under Good Manufacturing Practice conditions with per-batch testing before release. Protocols use allogeneic adult mesenchymal stem cells derived from adipose tissue or umbilical cord, depending on the protocol, with donor screening as described above.
- Injection. The intra-articular injection is performed as an outpatient procedure at your chosen clinic: Playa del Carmen, Cancun or Los Algodones. The Medical Director reviews your plan again on arrival, before anything is administered.
- Same-day and short-term monitoring. You are monitored after the procedure, and given written aftercare instructions covering activity, expected soreness and what warrants immediate contact.
- Remote follow-up. Structured follow-up continues after you fly home, so that changes in pain and function are tracked rather than assumed.
Most knee patients are in Mexico for a short stay rather than an extended one. See how long patients stay for what to plan around. If you are travelling from the United States, travelling from the US for treatment covers border crossing and documentation.
Why patients evaluate Mexico for knee stem cell therapy
Two things are true at once here, and both belong on the page.
The regulatory position is different. The FDA has not approved regenerative medicine products for any orthopedic condition [9], which means intra-articular stem cell treatment for knees is not available as an approved therapy in the United States outside a clinical trial. That is a statement about regulatory status, not a verdict on safety. In Mexico, treatments of this type are delivered by clinics certified by COFEPRIS, the federal health regulator. GIOSTAR Mexico holds COFEPRIS certification and operates under GMP laboratory practice with per-batch testing.
Certification and evidence are two separate assurances. A COFEPRIS certificate confirms that a clinic is authorized to operate and has met the regulator’s standards for facilities and practice. The clinical evidence is a separate question, and the findings above apply in Mexico exactly as they apply anywhere else. You deserve both stated plainly, and both are on this page.
What Mexico does offer knee patients concretely: treatment without a trial-enrolment requirement, a materially lower price than US regenerative clinics, and a short-stay outpatient pathway from three locations reachable from the US and Canada.
Knee stem cell treatment compared with PRP, cortisone, physical therapy and knee replacement
| Option | What it is | What the evidence base looks like | Usual role | What to keep in mind |
|---|---|---|---|---|
| Stem cell injection (allogeneic MSC) | Donor-derived MSCs injected into the joint space | Randomised trials of allogeneic adipose and umbilical cord MSCs report pain and function improvement at 6–12 months; a meta-analysis of 8 trials in 502 patients found significant WOMAC gains at 6 and 12 months; a consistent safety record across trials | Considered when conservative care has stopped working and replacement is not yet wanted | An emerging therapy; benefit is measured over 6–12 months, longer-term and structural data are still being gathered, and it is not approved for orthopedic use in the US |
| PRP injection | Concentrated platelets from your own blood | Studied more extensively than stem cells in knee OA; results still mixed across trials | Often tried before or alongside other injections | Effect size and durability debated; preparations are not standardized |
| Corticosteroid injection | Anti-inflammatory steroid into the joint | Long-established; well documented short-term relief. Matched cell therapy at 12 months in MILES (480 patients); was outperformed by a standardised UC-MSC product in a 30-patient pilot | Fast symptom control during a flare | Relief is typically weeks to a few months; repeat use raises cartilage concerns |
| Physical therapy | Progressive strengthening and load management | The best-evidenced conservative treatment for knee OA | First-line, and continues to matter alongside any injection | Requires sustained effort; may be insufficient in advanced disease |
| Total knee replacement | Surgical replacement of the joint surfaces | The definitive treatment for severe disease, with decades of outcome data | Advanced, bone-on-bone disease that has not responded to other care | Major surgery, extended recovery, and implants have a limited lifespan |
A note on direct comparisons: head-to-head trials exist, but they are few, small and not yet in agreement. A reliable ranking of these options is still being built, so this page gives you the trials themselves rather than a verdict.
Knee stem cell therapy cost at GIOSTAR Mexico
Musculoskeletal protocols at GIOSTAR Mexico, which includes knee treatment, range from $6,000 to $13,000 USD. Where a specific case falls in that range depends on four things: the degree of degeneration seen on your imaging, the number of vials your protocol calls for, the design of the protocol itself, and the monitoring and follow-up it includes. You receive a specific figure after imaging review, not before, and not from a price list.
For comparison, knee osteoarthritis treatment at US regenerative clinics is commonly quoted at $25,000 to $50,000. Across treatment categories, GIOSTAR Mexico’s pricing runs 50–80% below US equivalents.
What the package covers: initial evaluation, laboratory work and imaging review, protocol design, cell processing and quality assurance, the treatment sessions themselves, post-treatment monitoring, aftercare, and concierge support. Accommodation, IV nutritional therapy and a nutritional consultation are included. Hyperbaric oxygen therapy is available at the Los Algodones clinic only. There are no separate charges bolted on afterwards.
Stem cell therapy is only one component of the care we provide. Depending on each patient’s needs, treatment may also include IV nutritional therapy with vitamins and minerals to help prepare the body, exosome therapy to support and complement the regenerative effects of stem cells, hyperbaric oxygen therapy (at our Los Algodones clinic), nutritional consultations before and after treatment, and, in some cases, physical therapy. By combining these supportive therapies, we aim to create an environment that helps optimize the treatment experience and supports the body’s natural healing and recovery processes.
Third-party medical financing is available for qualifying US patients, payment plans are available, and the consultation that determines your eligibility is free.
For treatment categories other than musculoskeletal and a full breakdown of what drives pricing, see the stem cell therapy cost in Mexico guide.
Paying for treatment
The consultation that determines whether you are a candidate is free, and you receive a specific figure for your protocol before any commitment.
For US patients who prefer to spread the cost, GIOSTAR Mexico offers third-party medical financing that can cover up to the full cost of treatment, subject to the lender’s approval. Financing is not currently available to patients in Canada or Europe. Major cards, wire transfer and installment arrangements are also accepted.
Because the package is all-inclusive, the figure you are quoted is the figure you pay. Accommodation, IV nutritional therapy, the nutritional consultation, monitoring and follow-up are already inside it. See financing and payment options for full details.
What is arranged for you once you are accepted
Travelling abroad for treatment is the part most patients worry about. It is also the part GIOSTAR Mexico handles.
Transfers. Airport, hotel and clinic transfers are arranged for you. Patients travelling to Los Algodones are met at the border or picked up from Yuma Airport.
Accommodation. Lodging is included in your package. In Los Algodones, GIOSTAR Mexico works with Hotel Hacienda and Hotel Cielito Lindo.
Language assistance. Support in your own language is available throughout, so nothing about your care is lost in translation.
A second clinical review on arrival. The Medical Director reviews your plan again before anything is administered.
One point of contact. The same coordination runs from your first call through to long-term post-treatment follow-up, so you are not handed between departments at any stage.
Practical planning details are covered in how long patients stay, and US patients will find border and documentation guidance in travelling from the US for treatment.
How to evaluate any knee stem cell clinic before you pay
Take these to whichever clinics you are considering, this one included. A clinic that answers all ten without hedging is behaving differently from one that changes the subject. GIOSTAR Mexico’s own answers are given underneath each question.
- What exactly are you injecting, and where do the cells come from? You should get a specific answer: autologous (your own cells, from fat or bone marrow) or allogeneic (donor cells, from adipose tissue or umbilical cord tissue), and how they were prepared. The ISSCR names an undocumented cell source as a warning sign [10]. GIOSTAR Mexico: Allogeneic adult mesenchymal stem cells from adipose tissue or umbilical cord tissue, depending on the protocol; adipose donors are 18–22 years old and screened through cytotoxicity and oncogenicity testing.
- Is the product tested batch by batch, and what are the release criteria? Cell products cannot be quality-tested the way a mass-produced drug can. Batch testing is what stands in for that, and it is the variable Cochrane blamed for the field’s low certainty. GIOSTAR Mexico: Cells are prepared under GMP conditions with per-batch testing before release.
- Which regulator authorizes this clinic, and what does that authorization actually cover? Ask for the license, and ask what it covers. Note the difference between a clinic being licensed and a treatment being proven. GIOSTAR Mexico: COFEPRIS-certified. Licence verification is provided to prospective patients on request, so you can check it before you commit.
- Who reviews my imaging before you accept me, and what would make you turn me down? A clinic that can describe its exclusion criteria clearly is a clinic that applies them. GIOSTAR Mexico: Physician review of X-ray or MRI plus bloodwork precedes any protocol. Advanced bone-on-bone degeneration, structural instability, pregnancy, active infection, active cancer and eye conditions are among the reasons candidates are declined.
- What does the published evidence say for your specific cell type, and will you show me the uncertainty as well as the promise? Ask for named sources with dates, and ask specifically about the cells they intend to use. Category-level claims are a starting point, and the specifics are the real answer. GIOSTAR Mexico: The evidence section above, with the head-to-head comparisons and what each of them showed.
- Will I receive a written consent document setting out the treatment’s status and its risks? The ISSCR advises that you should receive a consent form for any investigational stem cell treatment, whether or not it is part of a trial, setting out the status of the treatment and its specific risks. GIOSTAR Mexico: Risks and expectations are discussed during screening, and consent documentation is provided before treatment.
- Who performs the injection, and what are their credentials in treating knees specifically? Cell biology expertise and clinical injection expertise are not the same skill. GIOSTAR Mexico: Protocols were established by Dr. Anand Srivastava, Chairman and Co-Founder of GIOSTAR, whose background includes the stem cell core facility at the Salk Institute and work on the UCLA stem cell program. Treatment is delivered by the clinical team, and the Medical Director reviews your plan on arrival.
- What happens if there is a complication while I am abroad, and who pays for it? The ISSCR specifically advises asking about the cost of emergency care if something goes wrong outside your own country, and what your insurance covers where. GIOSTAR Mexico: Post-procedure monitoring and written aftercare instructions are provided, with a named contact route. Confirm your own travel and medical cover before you book.
- What is the total price, and what is not included? Hidden costs are on the ISSCR’s warning list for a reason. GIOSTAR Mexico: $6,000–$13,000 for musculoskeletal protocols, inclusive of the package listed above, including accommodation. Flights and meals outside the program are separate.
- What does follow-up look like after I fly home? Look for a defined follow-up schedule rather than an open invitation to call. GIOSTAR Mexico: Structured remote follow-up after you return home, tracking pain and function over time.
Two further pointers from the ISSCR’s patient guidance: look for evidence that goes beyond patient testimonials, and ask questions when the same cells are offered for a long list of unrelated conditions. Give yourself time, too. A second opinion from a doctor you trust is always worth having, and a good clinic will encourage you to take it.
Certification, quality and medical oversight
COFEPRIS certification. GIOSTAR Mexico’s clinics in Playa del Carmen, Cancun and Los Algodones are COFEPRIS-certified, and licence verification is available to any prospective patient who asks for it.
Laboratory standards. Cells are processed under Good Manufacturing Practice conditions with per-batch testing prior to release, using screened allogeneic donor material.
Scientific leadership. GIOSTAR is part of the Global Institute of Stem Cell Therapy and Research, headquartered in San Diego. Dr. Anand Srivastava, Chairman and Co-Founder, established all clinical and research protocols at GIOSTAR Mexico. He has held research positions since 1997, contributed to the establishment of the stem cell core facility at the Salk Institute, worked on the UCLA stem cell program, served as a Visiting Fellow at the National Research Institute in Nansei, Japan, reviews for multiple stem cell journals, and advises governments on stem cell policy.
Medical disclaimer. This page is for general information and does not constitute medical advice, diagnosis or treatment. Stem cell therapy for knees is not approved by the US Food and Drug Administration for orthopedic conditions, and current evidence for its effectiveness is limited and of low certainty. Individual results vary. No outcome is guaranteed. Discuss any treatment decision with your own physician before proceeding.
Frequently Asked Questions
Q: Does stem cell therapy for knees actually work?
A: Randomised trials of allogeneic adipose and umbilical cord MSCs report improvement in pain and function at 6 and 12 months, with a consistent safety record. In one trial a standardised umbilical cord product outperformed a corticosteroid injection over 12 months, and in the largest head-to-head trial, in 480 patients, cell therapy performed on a par with corticosteroid. Research continues on how long the benefit lasts beyond a year.
Q: What kind of stem cells does GIOSTAR Mexico use for knees?
A: Allogeneic adult mesenchymal stem cells, meaning donor cells rather than your own, derived from adipose tissue or umbilical cord tissue depending on the protocol. Adipose donors are healthy individuals aged 18 to 22, screened through cytotoxicity and oncogenicity testing. Cells are prepared under GMP conditions with per-batch testing before release. Protocols for joint conditions administer between 105 and 140 million stem cells.
Q: Why does a certified laboratory matter?
A: Because cell products are biological rather than chemical, and the largest review of this field found that cell source, preparation and dose varied widely between studies. GMP conditions, defined dosing and batch release testing control that variability, so you receive a product of known origin, known dose and tested quality.
Q: How much does stem cell therapy for knees cost in Mexico?
A: Musculoskeletal protocols at GIOSTAR Mexico, including knee treatment, range from $6,000 to $13,000 USD. Your figure depends on the degree of degeneration on imaging, the number of vials, the protocol design and the monitoring included. US regenerative clinics commonly quote $25,000 to $50,000. You receive a specific quote after imaging review.
Q: Am I a candidate if my knee is bone-on-bone?
A: Often not, and you will be told so directly. Advanced degeneration leaves little remaining tissue for injected cells to work with, and structural instability is a separate problem that an injection does not address. Most published trials enrolled patients with moderate disease. A physician reviews your X-ray or MRI first, and if this is not the right option you will hear why and what may suit you better.
Q: Is it safe?
A: The safety record across the randomised trials cited on this page is reassuring: no treatment-related serious adverse events were reported in any of them. As with any injection into a joint there is a small risk of infection, which your physician discusses with you before treatment, and GIOSTAR Mexico’s screening is designed to identify anyone for whom the procedure would not be appropriate.
Q: Will this let me avoid knee replacement?
A: That is not something anyone can honestly promise, and research has not yet shown that stem cell injection prevents or delays knee replacement. Treatment is offered as a way to help manage symptoms, and many patients pursue it hoping to stay comfortable and active for longer before considering surgery.
Q: How long do I need to be in Mexico?
A: Knee protocols are outpatient, so most patients plan a short stay rather than an extended one. Because the cells are donor-derived, there is no separate harvest procedure to recover from. Your coordinator confirms the schedule once your protocol is set.
Find out where your knee actually stands
Everything on this page is general. Your knee is not.Send your health history and your existing X-ray or MRI, and a physician will review your specific case and tell you whether stem cell therapy for knees is a reasonable option for you, including a straight answer if it is not the right fit, and what may help instead. You will also receive a specific price for your protocol rather than a range. There is no cost and no obligation.
Request your free consultation today.
.
📚 References
- Whittle SL, Johnston RV, McDonald S, Worthley D, Campbell TM, Cyril S, Bapna T, Zhang J, Buchbinder R. Stem cell injections for osteoarthritis of the knee. Cochrane Database of Systematic Reviews. 2025, Issue 4. Art. No.: CD013342. DOI: 10.1002/14651858.CD013342.pub2.
- Safety and efficacy of an allogeneic adipose-derived mesenchymal stem cell preparation (MAG200) in the treatment of knee osteoarthritis: a Phase I/IIa randomised controlled trial. Osteoarthritis and Cartilage Open, 2024. PMID 39161739.
- Kasagga A, Verma A, Saraya E, Haque MS, Khan SM, Hamid PF. Autologous versus allogeneic adipose-derived mesenchymal stem cell therapy for knee osteoarthritis: a systematic review, pairwise and network meta-analysis of randomized controlled trials. Cureus. 2025 Apr 21;17(4):e82713. DOI: 10.7759/cureus.82713.
- Cao M, Ou Z, Sheng R, et al. Efficacy and safety of mesenchymal stem cells in knee osteoarthritis: a systematic review and meta-analysis of randomized controlled trials. Stem Cell Research & Therapy. 2025 Mar 7;16(1):122. DOI: 10.1186/s13287-025-04252-2.
- Matas J, Orrego M, Amenabar D, et al. Umbilical cord-derived mesenchymal stromal cells (MSCs) for knee osteoarthritis: repeated MSC dosing is superior to a single MSC dose and to hyaluronic acid in a controlled randomized phase I/II trial. Stem Cells Translational Medicine. 2019 Mar;8(3):215–224. DOI: 10.1002/sctm.18-0053.
- Matas J, García C, Poblete D, et al. A phase I dose-escalation clinical trial to assess the safety and efficacy of umbilical cord-derived mesenchymal stromal cells in knee osteoarthritis. Stem Cells Translational Medicine. 2024;13(3):193–203. DOI: 10.1093/stcltm/szad088.
- Pico OA, Espinoza F, Cádiz MI, et al. Efficacy of a single dose of cryopreserved human umbilical cord mesenchymal stromal cells for the treatment of knee osteoarthritis: a randomized, controlled, double-blind pilot study. Cytotherapy. 2025;27(2):188–200. DOI: 10.1016/j.jcyt.2024.09.005.
- Mautner K, Gottschalk M, Boden SD, et al. Cell-based versus corticosteroid injections for knee pain in osteoarthritis: a randomized phase 3 trial. Nature Medicine. 2023 Dec;29(12):3120–3126. DOI: 10.1038/s41591-023-02632-w.
- US Food and Drug Administration. Important Patient and Consumer Information About Regenerative Medicine Therapies. Content current as of 8 April 2024.
- International Society for Stem Cell Research. Patient Resources / Frequently Asked Questions for Patients. isscr.org/patients.
